Skip to main content
logo
Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
3.680
+0.310 (9.20%)
At close: Nov 6, 2026, 4:00 PM EST
3.680
0.00 (0.00%)
Pre-market: Nov 9, 2026, 5:43 AM EST

Immuneering Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
----0.322.08
Revenue Growth
-----84.76%-10.02%
Cost of Revenue
----0.161.15
Gross Profit
----0.160.93
Selling, General & Admin
19.2317.316.0816.7615.618.27
Research & Development
54.6242.0547.9641.6236.2726.54
Amortization of Goodwill & Intangibles
0.030.030.030.030.03-
Operating Expenses
73.8859.3864.0758.4151.934.81
Operating Income
-73.88-59.38-64.07-58.41-51.74-33.89
Interest & Investment Income
5.513.042.593.611.010.17
Other Non Operating Income (Expenses)
0.360.160.180.320.050
EBT Excluding Unusual Items
-68-56.18-61.3-54.49-50.68-33.71
Gain (Loss) on Sale of Investments
1.50.160.261.020.17-0.13
Pretax Income
-66.5-56.02-61.04-53.47-50.51-33.84
Income Tax Expense
------0.31
Net Income
-66.5-56.02-61.04-53.47-50.51-33.54
Net Income to Common
-66.5-56.02-61.04-53.47-50.51-33.54
Net Income Growth
------
Shares Outstanding (Basic)
654430282614
Shares Outstanding (Diluted)
654430282614
Shares Change
81.94%46.80%5.51%7.69%93.84%175.00%
EPS (Basic)
-1.03-1.27-2.04-1.88-1.91-2.46
EPS (Diluted)
-1.03-1.27-2.04-1.88-1.91-2.46
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-61.81-45.49-55.08-49.31-44.84-30.91
Free Cash Flow Per Share
-0.95-1.03-1.84-1.74-1.70-2.27
Gross Margin
----50.11%44.56%
Operating Margin
-----16325.77%-1629.17%
Profit Margin
-----15937.29%-1612.33%
Free Cash Flow Margin
-----14148.44%-1486.17%
EBITDA
-73.52-59.02-63.69-58.06-51.47-33.84
D&A For EBITDA
0.360.350.390.350.280.05
EBIT
-73.88-59.38-64.07-58.41-51.74-33.89
SEC Filings: 10-K · 10-Q